Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers

Study Overview
=================
Brief Summary
-----------------
Thrombotic biomarkers and angiographic characteristics were compared among the de novo patients of central serous chorioretinopathy (CSC), polypoidal choroidal vasculopathy (PCV) and the control.

Official Title
-----------------
Analysis of Plasminogen Activator Inhibitor-1 Level in Chronic Serous Chorioretinopathy and Polypoidal Choroidal Vasculopathy

Conditions
-----------------
Central Serous Chorioretinopathy, Polypoidal Choroidal Vasculopathy

Intervention / Treatment
-----------------
* Other: Blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CSC neurosensory detachment in optical coherence tomography (OCT) focal leakage in fluorescein angiography (FAG) and/or late choroidal hyperpermeability in indocyanine green angiography (ICGA) PCV subretinal and/or sub-retinal pigment epithelial fluid in OCT branching vascular network and/or polyps in ICGA Control epiretinal membrane (ERM) without underlying systemic, ophthalmic disease other than ERM Exclusion Criteria: Previous history of using steroid (oral, topical) Previous history of CSC/PCV Previous history or evidence of intraocular inflammation including uveitis Co-existing retinal or choroidal diseases History of allergic reaction to fluorescein or indocyanine green dye Underlying systemic conditions that could affect the thrombotic profiles (e.g. diabetes, hypertension, metabolic syndrome, coronary artery disease, cerebrovascular diseases, stroke, chronic renal failure, current smoker, pregnancy, sleep disorder)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Central serous chorioretinopathy<br>De novo eligible CSC patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis. | Other: Blood sampling<br>* Sampling the blood including DNA to investigate the thrombotic profile<br>|
| Polypoidal choroidal vasculopathy<br>De novo eligible PCV patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis. | Other: Blood sampling<br>* Sampling the blood including DNA to investigate the thrombotic profile<br>|
| Epiretinal membrane<br>Idiopathic ERM patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis. | Other: Blood sampling<br>* Sampling the blood including DNA to investigate the thrombotic profile<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum Fibrinogen in active PCV and CSC patients | Serum Fibrinogen (mg/dl) | Less than 1 week after initial diagnosis | 
| Serum Factor VIII activity in active PCV and CSC patients | Serum Factor VIII activity (%) | Less than 1 week after initial diagnosis | 
| Serum Plasminogen activity in active PCV and CSC patients | Serum Plasminogen activity (%) | Less than 1 week after initial diagnosis | 
| Serum D-dimer in active PCV and CSC patients | Serum D-dimer (μg/mL(FEU)) | Less than 1 week after initial diagnosis | 
| Serum Fibrin degradation product in active PCV and CSC patients | Serum Fibrin degradation product (μg/mL) | Less than 1 week after initial diagnosis | 
| Serum PAI-1 antigen in active PCV and CSC patients | Serum PAI-1 (plasminogen activator inhibitor-1) antigen (ng/mL) | Less than 1 week after initial diagnosis | 
| Serum PAI-1 SNP genotyping in active PCV and CSC patients | Serum PAI-1 SNP(single nucleotide polymorphism) genotyping | Less than 1 week after initial diagnosis | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characteristics of fluorescein angiography in active PCV and CSC patients | Numbers of leaking points of fluorescein dye in fluorescein angiography | Less than 1 week after initial diagnosis | 
| Characteristics of indocyanine green angiography in active PCV and CSC patients | Numbers of hyperfluorescent spots in indocyanine green angiography | Less than 1 week after initial diagnosis | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Plasminogen activator inhibitor-1, Wide angle fluorescein angiography, Choroid